Evidence map›Paper›PMID 40473462›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Sara S Rinne, Daniela Burnes Vargas, Shin Seo, Darren Veach, Michael R McDevitt, Brett A Vaughn, Hong Xu, Hong-Fen Guo, Edward K Fung, Elisa de Stanchina and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sara S RinneMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.
Daniela Burnes VargasMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.
Shin SeoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Darren VeachDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael R McDevittDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Brett A VaughnMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.
Hong XuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Hong-Fen GuoDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Edward K FungDepartment of Medical Physics, Weill Cornell Medicine, New York, New York.
Elisa de StanchinaMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Ileana C MirandaLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and Rockefeller University, New York, New York.
Steven M LarsonMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Nai Kong V CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sarah M ChealMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York; smc4002@med.cornell.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
DOTA-based pre-targeting of alpha emittersR01CA233896 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEAL, SARAH MARIE · 2019 to 2023
$3.4M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA233896
6 · The paper itself

Abstract

Radioimmunotherapy using

Indexed as

ActiniumAlpha ParticlesBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticRadioimmunotherapyAnimalsCell Line, TumorFemaleHumansMiceTissue DistributionXenograft Model Antitumor AssaysActiniumActinium-225ERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesactinium-225breast cancerpretargeted radioimmunotherapytargeted alpha therapytrastuzumab

Identifiers

PMID40473462
PMCPMC12582181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.